Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 1998

View Archived Issues

Company Profile: CytoMed

Gliatech: Q4 and FY 1997 highlights

Sepracor: year-end 1997 highlights

Additional phase I/II data reported for Panretin Gel in KS

Genetix licenses gene therapy technologies from Dana-Farber

NIH offers potential tuberculosis vaccine technology for licensing

Milestone reached in Corvas/Pfizer NIF collaboration

Takeda exercises option to develop therapeutic protein

NIH will license technology that may lead to new HCV vaccines

Saruplase found equivalent to streptokinase in COMPASS trial

Neuropeptide Y Y2 agonists prepared at Peptech/CRC

Vitamin D analogues with promising profile from Leo

Role defined for Lp(a) in heart disease

Boehringer Ingelheim reveals new antiinflammatory agents

Penclomedine metabolite shows comparable anticancer efficacy, reduced neurotoxicity

Vitamin C protects blood vessels in diabetic patients

Anticoagulants under development at Astra

Cell Pathways/U. of Arizona study compounds for precancerous lesions

CFC-222 compared to other fluoroquinolones in vitro and in vivo

Ongoing clinical trials of Topiglan confirm positive early results

Phase I/II trial results reported for OncoVax-P formulated with JenVax-100a

Elan/Sano merger approved by Sano stockholders

Once-daily formulation of paroxetine submitted for FDA review

Select Therapeutics licenses cancer-related technology

NIH researchers discover how light shuts off melatonin production

Idec, SKB announce development plans for clenoliximab

Ten-year gene therapy collaboration initiated by Transgene and Human Genome Sciences

FDA okays labeling change for Pulmozyme